[Click eStock] "NKMax Expected to Become a Global New Drug Development Company"

Published 27 Apr.2023 08:49(KST)

KB Securities analyzed on the 27th that NKMax has a growing potential to become a global new drug development company.

Researcher Im Clinical-guk of KB Securities stated, "We expect the final results of the Phase 1 clinical trial for 'SNK01' related to sarcoma in the first half of this year," and added, "Combination therapy clinical trials are underway with Keytruda and Bavencio, respectively."

He continued, "Expectations are rising for positive data not only from the interim data of the Phase 1 combination therapy group but also from the final results," and added, "Interim data from the Phase 1/2a clinical trial for TKI-resistant non-small cell lung cancer will also be announced in early June."

He analyzed, "The clinical trial for the allogeneic NK cell therapy 'SNK02' will also begin," and explained, "Clinical trials targeting gastric cancer and solid tumors are underway in Korea and the United States, respectively, with approval received last year." Furthermore, he emphasized, "The commercialization potential of SNK01 for neurodegenerative brain disease treatment should also be noted," adding, "On the 29th of last month, it became the first domestic bio company to receive compassionate use approval (EAP) from the U.S. FDA for treating Parkinson's disease patients."

Researcher Im said, "If SNK01 is confirmed to act as an immune cell in the brain and demonstrate therapeutic effects, it could emerge as the first company developing NK cell therapies for degenerative brain diseases," and introduced, "On the 17th, the U.S. subsidiary NKGen Biotech announced a merger with Graf Acquisition, a special purpose acquisition company (SPAC) listed on the New York Stock Exchange (NYSE)."

He expressed expectations, "This could lead to a listing as early as the third quarter of this year," and added, "After listing, acceleration of clinical trials with global big pharma, improvement of financial structure, and rapid increase in corporate value are expected."